Eton Pharmaceuticals, Inc.: gross profit
Gross profit for Eton Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Eton Pharmaceuticals, Inc. financial histories
What this measure means
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
Exact concept: us-gaap:GrossProfit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 42,740,000 | USD | 2026-03-19 | 10-K · 0001437749-26-009059 |
| 2024-01-01 | 2024-12-31 | 23,411,000 | USD | 2026-03-19 | 10-K · 0001437749-26-009059 |
| 2023-01-01 | 2023-12-31 | 21,061,000 | USD | 2026-03-19 | 10-K · 0001437749-26-009059 |
| 2022-01-01 | 2022-12-31 | 14,318,000 | USD | 2025-03-18 | 10-K · 0001437749-25-008136 |
| 2021-01-01 | 2021-12-31 | 19,005,000 | USD | 2024-03-14 | 10-K · 0001437749-24-007853 |
| 2020-01-01 | 2020-12-31 | -397,000 | USD | 2023-03-16 | 10-K · 0001493152-23-007933 |
| 2019-01-01 | 2019-12-31 | 506,000 | USD | 2022-03-16 | 10-K · 0001493152-22-006990 |
Related financial histories
- Eton Pharmaceuticals, Inc.: total assets
- Eton Pharmaceuticals, Inc.: total liabilities
- Eton Pharmaceuticals, Inc.: stockholders equity
- Eton Pharmaceuticals, Inc.: cash and cash equivalents
- Eton Pharmaceuticals, Inc.: net income or loss
- Eton Pharmaceuticals, Inc.: operating cash flow
- Eton Pharmaceuticals, Inc.: capital expenditure payments
- Eton Pharmaceuticals, Inc.: contract revenue excluding tax
- Eton Pharmaceuticals, Inc.: financing cash flow
- Eton Pharmaceuticals, Inc.: investing cash flow
- Eton Pharmaceuticals, Inc.: retained earnings or deficit
- Eton Pharmaceuticals, Inc.: basic weighted-average shares
- Eton Pharmaceuticals, Inc.: basic earnings per share
- Eton Pharmaceuticals, Inc.: income tax expense or benefit
- Eton Pharmaceuticals, Inc.: net property, plant and equipment
- Eton Pharmaceuticals, Inc.: share-based compensation expense
- Eton Pharmaceuticals, Inc.: operating income or loss
- Eton Pharmaceuticals, Inc.: current assets
- Eton Pharmaceuticals, Inc.: interest expense
- Eton Pharmaceuticals, Inc.: current liabilities
- Eton Pharmaceuticals, Inc.: current accounts payable
- Eton Pharmaceuticals, Inc.: net finite-lived intangible assets
- Eton Pharmaceuticals, Inc.: net current accounts receivable
- Eton Pharmaceuticals, Inc.: operating expenses
- Eton Pharmaceuticals, Inc.: net inventory
- Eton Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Eton Pharmaceuticals, Inc. / CIK 0001710340
- Captured
- 2026-09-19T11:20:36.499Z
- SEC response SHA-256
f7f154bb5484ead9734e7792fe9226c296b72a5adb5779a7e452499ba4d8b45b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001710340.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))